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This policy research aims to map patient access barriers to biologic treatments, to explore how increased uptake of biosimilars may
lower these hurdles and to identify factors limiting the increased utilisation of biosimilars. A policy survey was developed to review
these questions in 10 Central and Eastern European (CEE) and Commonwealth of Independent States (CIS) countries. Two experts
(one public and one private sector representative) from each country completed the survey. Questions were related to patient access,
purchasing, clinical practice, and real-world data collection on both original biologics and biosimilars. Restrictions on the number
of patients that can be treated and related waiting lists were reported as key patient access barriers. According to respondents,
for both clinicians and payers the primary benefit of switching patients to biosimilars would be to treat more patients. However,
concerns with therapeutic equivalence and fear of immunogenicity may reduce utilisation of biosimilars. Similar limitations in
patient access to both original biologics and biosimilars raise concerns about the appropriateness and success of current biosimilar
policies in CEE and CIS countries.The conceptual framework for additional real-world data collection exists in all countries which
may provide a basis for future risk-management activities including vigorous pharmacovigilance data collection.
1. Introduction
All European countries are facing the challenge of how to
cover and reimburse high priced patent-protected medicines
such as biologic treatments from their limited health care
budget. Despite a greater unmet medical need due to
shorter life expectancy and worse overall health status of the
population compared to higher income Western European
countries, financial constraints are greater in countries of
Central and Eastern Europe (CEE) and Commonwealth of
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Independent States (CIS) [1]. However, due to external price
referencing, prices of newly developed medicines are often
adjusted to the price prevailing in higher income countries,
and launch sequence strategies are carefully designed by
manufacturers to minimize the price erosion in countries
with the greatest market potential [2–4]. In contrast, the cost
of health services is much lower in CEE and CIS countries;
therefore, a price similar to that in higher income countries
cannot be justified based on cost savings from avoided
medical events or hospitalisation [5]. As a consequence,
the majority of new medicines, which may be cost-effective
in higher income European countries, are not necessarily
cost-effective in CEE and CIS countries [6]. Furthermore,
lower income countries are not able to pay as much for
improvements in mortality and morbidity. Still, as there is a
strong political pressure to provide access to and reimburse-
ment for such medicines, payers in lower income countries
apply special cost-containment measures to facilitate the
sustainability of health care financing. Confidential price
reductions or discountsmay be a reasonablemethod to tackle
the narrow international price corridor of pharmaceuticals
due to external price referencing: however, as several higher
income European countries also benefit from confidential
pricing agreements, other tools are also necessary. Further
frequently applied—sometimes contradictory—methods to
control access and pharmaceutical spending in countries with
severe economic constraints include the following: delayed
reimbursement of biologic medicines; restricted volume of
patients on reimbursed biologics; limited treatment duration;
introduction of waiting lists; and narrowed reimbursed indi-
cation compared to the registered indication specified in the
Summary of Product Characteristics [7–10]. The existence
of these barriers has been based on anecdotal evidence in
the CEE and CIS region: hence, more field research, such
as expert interviews focusing on these issues, is required
to formulate international and national policies to reduce
inequities in patient access and health.
The policy rationale for allowing biosimilar entry is
analogous to that for generic entry following patent expiry
for small molecules. Once patents expire, competing copies
or near copies are permitted to enter the market. This
competition will lead to lower prices, but generally as a
function of the number of entrants. However, the costs
of developing a biosimilar are much higher than those
for a small molecule follow-on medicine. For the former,
regulators require noninferiority head-to-head clinical trials
versus the originator biologic medicine. For the latter, they
require only bioequivalence assessed using laboratory meth-
ods. Generally, market prices decline with the number of
entrants and in case of generic competition are often 10–20%
of the originator’s price.Markets for biologics with competing
biosimilars may have fewer entrants and less price reduction,
meaning that access will be more limited. Outcomes-based
agreement that allow differential pricing in CEE and CIS
countries could help to overcome this effect [11].
A large number of original biologic medicines is about
to lose patent protection in the near future [12]. In fact, the
so-called “patent cliff” for biologics has already begun since
the top ten selling products in 2011 (worth 37.6% of the total
biologicsmarket value—almost 60 billionUSD in global sales
as of 2011) will lose their market exclusivity between 2012 and
2019 [13]. High-quality biosimilars authorised by reputable
regulatory agencies such as the European Medicines Agency
(EMA) or the Food and Drug Administration (FDA) offer
therapeutic alternatives to original biologics at reduced price
[14, 15]. However, the clinical and economic benefit of such
biosimilars is not only to generate savings for health care
budgets but also to improve patient access to reimbursed
biologic products at these lower prices [16].
Compared to small molecule products, biologic therapies
with large molecule weight and complex chemical structure
cannot be reproduced in a completely identical form [17].
Therefore, confirmation of biosimilarity requires a more
comprehensive evaluation and comparison of the quality,
safety, and efficacy of the similar biologic product and its
originator [18]. Despite the application of rigorous criteria,
a potential concern about biosimilars is the extrapolation of
clinical data required for registration to all indications of the
original product [19].
A systematic literature review found that biosimilar
immunogenicity differs among active compounds suggesting
that immunogenicity of anti-drug antibodies should be an
important consideration in the treatment decision-making
process such as switching [20]. Some opinion leaders argue
that switching fromanoriginal biologicmedicine to a biosim-
ilar may induce increased immunogenic reactions [21, 22].
Recent systematic reviews showed, however, that switching
patients from the original chronic biologic therapy to a
biosimilar alternative was not associated with increased risk
of adverse reactions or loss of efficacy [23, 24]. Still, even with
these recent findings, the utilisation of biosimilars, especially
for patients on maintenance original biologic treatment, is
not an obvious alternative for many physicians and payers
[25–28].
The objectives of our policy research were to
(1) map the barriers of patient access to biologic mono-
clonal antibodies in CEE and CIS countries,
(2) explore how increased uptake of biosimilar mono-
clonal antibodies may lower these hurdles,
(3) identify factors limiting the increased utilisation of
biosimilar monoclonal antibodies.
2. Materials and Methods
A standardized English language survey was developed for
collecting feedback from policy experts in 10 CEE and
CIS countries, including Bulgaria, Czech Republic, Hungary,
Kazakhstan, Latvia, Lithuania, Poland, Romania, Russia, and
Slovakia. In each country, one expert from the public sector
and one from the private sector completed the survey (see
Table 1). Experts were selected based on their in-depth
knowledge on biosimilar pharmaceutical policies in their
own countries. Willingness to participate in the study was
confirmed by each expert prior to the distribution of the
survey, resulting in 100% overall response rate. The survey
was distributed in an Excel spreadsheet format. Answers were
received between March and September of 2015.
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Table 1: Affiliation of survey respondents.
Country Public sector Private sector
Academic policy expert HTA expert Payer/reimbursement committee Industry
Bulgaria X X
Czech Republic X X
Hungary X X
Kazakhstan X X
Latvia X X
Lithuania X X
Poland X X
Romania X X
Russia X X
Slovakia X X
Survey questions are summarized in Table 2. To gain
full understanding on the policy environment of each coun-
try, survey topics included a wide spectrum of questions
on registration, pricing, reimbursement, patient access to
reimbursed biologic treatment, and clinical practice such
as switching to biosimilar medicines, purchasing practices,
and collection of real-world data of original biologics and
biosimilars. Beyond the general national biosimilar policy
context, we specifically focused onmonoclonal antibodies for
the following reasons: (1) they have more complex protein
structure compared to first-generation biosimilars such as
erythropoietins, (2) they are associated with higher annual
treatment cost and budget impact [29], (3) the patents
of several monoclonal antibodies have expired recently or
will expire soon, and (4) they are used for longer-term
treatment in chronic conditions. Specific survey questions
were focused on three therapies: infliximab, trastuzumab,
and rituximab. However, at the time of this study period,
no biosimilar alternatives were available for trastuzumab
and rituximab. Thus, respondents were asked to express
their future expectations based on their current knowledge,
previous experiences, and individual perceptions. Terms used
in the survey were explained in a glossary to minimize
misunderstanding.
Iterative development of the survey tool covered prelimi-
nary interviews, field testing with local experts, and finalising
it based on their comments before release. The final survey
consisted of 4 spreadsheets (one for biologics in general and
one each for infliximab, trastuzumab, and rituximab, resp.).
Answer options were given in the survey, but respondents
had a chance to provide additional clarification by using an
“other (please specify)” option after each question. In addi-
tion, respondents could provide additional explanation or
references. Responses by the two experts from each country
were reconciled and in case of inconsistency disagreements
were solved via e-mail queries.
3. Results
Survey results are presented according to the study objectives,
reflecting some key areas of improving patient access to
biosimilar products.
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Figure 1: Frequency of reported patient access barriers to biologic
medicines in participant countries (𝑛 = 10).
3.1. Type of Patient Access Barriers to Biologic Treatments
in CEE and CIS. Figure 1 summarizes reported barriers of
timely patient access for reimbursed biologic medicines in
participant countries. Respondents had the opportunity to
select multiple options. Volume limits on the number of
patients who can be treated with public reimbursement,
related waiting lists, and limited duration of reimbursed
biologic treatment were reported as key barriers to patient
access to biologics. It is noteworthy that waiting lists were
reported even in haematology indications for rituximab and
oncology indications for trastuzumab in some countries.
Additionally, other barriers were mentioned: nonreimburse-
ment of complementary diagnostics, additional eligibility cri-
teria, or restricted reimbursement compared to the registered
indication (e.g., reimbursement only for metastatic disease).
3.2. Can Uptake of Biosimilars Lower Hurdles to Patient
Access for Biologic Medicines? Generally, the cost-saving
potential and the capacity to improve patient access to
reimbursed biologic medicines were mentioned as key ben-
efits of increased utilisation of biosimilars. According to
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Table 2: Questions of the reimbursement policy survey.
General questions related to all biologics and specific biologic therapies
(Q1) Please select which type of access limit is applied on the
patient population in the therapeutic use of original
biologics/biosimilars∗ in your country! (multiple choice)
(A) Access limit on the number of treated patients – i.e.
patients above the volume limit cannot be treated with
biologics
(B) Access limit on treatment duration/cycles – i.e.
treatment duration/cycles is maximised by payers
(C) Waiting lists for eligible patients – i.e. timely access
to biologics is not guaranteed for patients
(D) Patient co-payment for biologics – i.e. high
co-payment limits patient access
(E) Patient co-payment for related services – i.e. high
co-payment limits patient access to necessary
diagnostic services
(F) Limited institutional access – e.g. biologics can be
prescribed only in limited number of specialist centers
(G) Other (please specify)
(Q2) What are the main (or expected) benefits of a
clinician/payer from switching patients treated with original
biologics to a biosimilar∗ product? (multiple choice)
(A) More patients are treated with biologics
(B) Savings in health care budget
(C) Wider spectrum of treatment options
(D) Other (please specify)
(Q3) Is indication extrapolation accepted in your country by
payers/clinicians for biosimilars∗? (single choice)
(A) Yes + Answers in details
(B) No + Answers in details
(Q4) What are the main concerns (expected concerns) of a
clinician/payer of switching patients treated with original
biologics to biosimilars∗ in your country? (multiple choice)
(A) Fear of immunogenic reactions
(B) Concerns about manufacturing quality
(C) Concerns with similarity/therapeutic equivalence
(D) Fear of losing efficacy
(E) Other (please specify)
Specific questions related to experiences with biosimilar infliximab
(Q5) Please provide information about switching patients
from original infliximab to its biosimilar alternative in your
country! (single choice)
(A) Switching patients on maintenance original
infliximab treatment is not allowed
(B) Switching patients on maintenance original
infliximab treatment is allowed
(C) Switching patients on maintenance original
infliximab treatment is incentivized
(D) Switching patients on maintenance original
infliximab treatment is mandatory
(Q6) How switching to biosimilar infliximab is implemented
for patients on maintenance original infliximab treatment?
(single choice)
(A) Patients on maintenance original infliximab
treatment are switched to the cheapest biosimilar
alternative and stay on the same infliximab product (i.e.
single switch)
(B) Patients on maintenance original infliximab
treatment are always switched to another biosimilar
infliximab product when a cheaper biosimilar
alternative becomes available (i.e. multiple switch)
(C) Patients on maintenance original infliximab
treatment stay on the original infliximab product even
after the availability of cheaper biosimilar alternatives
(no switching)
(D) Other (please specify)
(Q7) Is tendering system applied for purchasing biosimilar
infliximab for specific patient groups (e.g. Rheumatoid
Arthritis, Psoriatic Arthritis, Colitis Ulcerosa, Crohn’s
Disease patients)? (multiple choice)
(A) Tendering system to purchase biosimilar infliximab
is not applied
(B) Centralized tendering system is applied at national
level i.e. one purchasing body coordinates the tendering
(C) Decentralized tendering system is applied at
regional level with national coordination i.e. tendering
rules are set nationally, but implemented regionally
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Table 2: Continued.
(D) Other (please specify)
General questions related to all biologics and specific biologic therapies
(Q8) Does your country apply incentives to generate real
world evidence related to the use biosimilar products? e.g.
quality of life data, survival data etc. (multiple choice)
(A) No, such incentives are not applied
(B) Yes, incentives are applied for collecting real world
evidence at national level
(C) Yes, incentives are applied for collecting real world
evidence through international collaborations
(D) Other (please specify)
(Q9) What are the potential data sources for real world
evidence of biosimilars∗ in your country? (multiple choice)
(A) Patient registries
(B) Payers’ database
(C) Other (please specify)
(Q10) Is the safety profile and the real world effectiveness of
biosimilars∗ assessed or evaluated after the registration?
(multiple choice)
(A) No
(B) Yes, safety profile is assessed
(C) Yes, effectiveness is evaluated
(D) Yes, cost-effectiveness is evaluated
(E) Other (please specify)
∗In different spreadsheets, original biologics were replaced with original infliximab, trastuzumab, or rituximab; biosimilars were replaced with biosimilar
infliximab, trastuzumab, or rituximab.
respondents’ opinions, both clinicians and payers expect that
treating more patients with reimbursed biologic medicines
(i.e., improved patient access to biologics) would be the
primary benefit of switching patients to biosimilars (Fig-
ure 2). The cost-saving potential of biosimilars for payers
and the increased number of treatment options for clinicians
were mentioned as secondary benefits. In the “other” option,
some respondents mentioned that even the price of original
products may be reduced due to price erosion generated
by internal price referencing. However, other respondents
expressed their concern that the generated cost savings may
be invested in other sectors of health care or even outside the
health care sector and thus not improve patient access.
3.3. Key Factors of Limited Patient Access to Biosimilars
3.3.1. Indication Extrapolation. According to this survey,
in general, payers in CEE/CIS countries seem to have
no concerns with extrapolation to indications. EMA reg-
istration is well accepted even if pivotal phase III data
were to be extrapolated to other indications without addi-
tional phase III clinical trial evidence. In contrast, respon-
dents in some countries—for example, in Bulgaria and in
Slovakia—expected negligible or restricted use of biosimilars
by clinicians in indications with only extrapolated data. This
is especially true in the field of oncology, where respondents
anticipated concerns from clinicians about extrapolating
biosimilar access to other indications.
3.3.2. Consequences of Switching Patients to Biosimilars.
According to respondents, immunogenicity after switching
the patients to biosimilar medicines could be a major con-
cern for clinicians, while limited information on therapeutic
equivalence with their originator could be problematic for
both clinicians and payers (see Figure 3). Interestingly, manu-
facturing quality was reported as a concern only in countries
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Figure 2: Expected benefits from treating more patients with
biosimilars (𝑛 = 10).
outside the European Union. Fear of political scandal as a
consequence of any adverse outcomes related to switching
was reported under “other” category.
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Figure 3: Concerns related to switching to biosimilars (𝑛 = 10).
3.4. Clinical Practice Related to Switching. In majority of
the countries, switching from original biologic medicine
to its biosimilar alternative is allowed. However, patients
on maintenance biologic treatment were expected to stay
on the original product. While majority of the countries
apply tenders for public procurement of biologic medicines,
the tender-winning biosimilars were expected to be used
for both treatment-naı¨ve patients and patients already on
maintenance biologics only in Lithuania, Poland, and Slo-
vakia. In Hungary, there are two separate tenders, one for
treatment-na¨ıve patients and one for patients already on
maintenance biologics. In all other countries, the tender
winner product should be prescribed only for the nontreated
patients, while treated patients may continue their previous
biologic treatment: switching to a more affordable biosimilar
alternative is not mandatory.
3.5. Framework for Postmarketing Data Collection. Postmar-
keting data collection related to medicines in general was
reported in all participant countries either in patient registries
or based on payers’ databases. Such activities are coordinated
by the health insurance fund in Hungary, Poland, and
Slovakia. Because of the abovementioned concerns related to
biosimilars, all countries except Russia reported that phar-
macovigilance data on biosimilars were regularly assessed or
planned to be assessed in the near future according to EMA
requirements. Additionally, national regulatory authorities
in Hungary and Slovakia were reported to reassess data on
effectiveness after registering a newbiosimilar to ensure equal
health gain with the originator product.
4. Discussion
While a few publications are available on biosimilar policies
in higher income countries [8, 30–32], the information
is even more limited from CEE/CIS countries [33]. Our
study indicates significant access restrictions to original
biologic medicines in CEE/CIS countries. Similar findings
were presented in a recent publication on disease-modifying
biologic antirheumatic medicines in 37 European countries,
including Russia and Turkey [10]. In our policy survey, real-
world experience for both the original and the biosimilar
products was available only for infliximab. Interestingly, the
reported restrictions in patient access were similar for origi-
nal and biosimilar infliximab. No improvement in the patient
access after biosimilar entry is an indicator of ineffective
biosimilar policies in CEE/CIS countries. The main objective
of biosimilar policy in countries with resource constrains
should be to improve health gain at the population level by
reducing barriers of patient access to reimbursed biologic
medicines—both originator and biosimilar [34]. Expected
barriers in patient access to biosimilar trastuzumab and
rituximab were reported to be similar to current barriers to
original trastuzumab and rituximab, as respondents did not
expect significant changes in biosimilar policies. This finding
calls for action and reconsideration of current policies in
order to facilitate the use of biosimilar medicines in CEE/CIS
countries [8].
Given reported access restrictions, it is not surprising
that increasing the number of patients receiving reim-
bursed biologic treatments was considered the primary ben-
efit of switching patients to biosimilar products in almost
all participant countries. Value-based purchasing strategies
require strong government interventions: biosimilars will not
become the preferred option in clinical practice if biosimilar
policies are ineffective and central government administra-
tion plays a passive role [35]. As with generic products, more
affordable biosimilars should be the first-line options for
the majority of patients [34]. This policy has been already
implemented for biosimilars in treatment-na¨ıve patients, for
example, in one Italian region and Poland, Denmark, and
Norway [8, 36–38].
Because infliximab, trastuzumab, and rituximab are
mainly used as long-term maintenance therapies in chronic
diseases, the societal benefits of access to more affordable
biosimilars can be maximised by both starting all de novo
patients on biosimilars and, asmuch as is clinically justifiable,
switching patients to biosimilars [9]. Although there is still
no supportive evidence related to the multiple switches of
patients between biosimilar alternatives, the single switch
of patients on original biologics to a biosimilar alternative
under medical supervision should be mandated or incen-
tivized [24]. This recommendation is in line with results of
recent systematic reviews demonstrating no increased risk
or loss of efficacy due to switching from original biologics
BioMed Research International 7
Table 3: Potential policy actions to maximise the societal benefit of biosimilars [9].
Areas for intervention Potential policy actions
Public administration of biosimilar medicines
Expedited price and reimbursement process to facilitate the timely
market entry of biosimilars
Introduction of administrative tools and policy measures to
incentivize the choice for more affordable biosimilars
Clinical guidelines
Multisource biologic medicines should be first-line biologic therapy
for all patients. More expensive patented biologic medicines with no
proven significant clinical benefit compared to biosimilar medicines
should be only second line options
Single switch of patients from an original biologic medicine to its
more affordable biosimilar alternative under medical supervision
should be mandated after patent expiry
Physicians should not only be informed about scientific evidence on
biosimilars but also guided on how to educate appropriately their
patients on these medicines
Evidence base of policy decisions
Cost-effectiveness or cost-utility analysis is applied to judge the full
economic value of biosimilar medicines except in those cases, when
biosimilar medicines are compared to their original biologic
alternative for treatment-na¨ıve patients.
Budget impact analysis is applied to estimate (1) the savings from
biosimilar medicines, if there is no patient access limit to biologic
medicines, or (2) the incremental budget, if patient access to biologic
medicines is restricted
Management of uncertainty related to policy decisions
Ex ante risk management: calculation of threshold for the risk of
immunogenicity, where not switching patients to biosimilar
medicines is the preferred option from the payers’ perspective
Ex post risk management: mandate of vigorous pharmacovigilance
data collection and risk-management plan in case of increased risk of
immunogenicity. The risk-management plan may even include
risk-sharing agreements with manufacturers of biosimilar medicines
to a biosimilar alternative [39–41]. Such practice is actively
encouraged in Poland [42].
As a general practice, our survey revealed that switching
to biosimilar products is allowed in many countries and
may be initiated at the discretion of the physician. This
passive policy was confirmed in a recent policy survey in CEE
countries [33]. In contrast, in Lithuania, Poland, and Slovakia,
where tender-winning products are likely to be used for
patients on maintenance original biologic therapy, manda-
tory switching to biosimilars is already partially implemented
[43]. If tenders are nonexclusives—that is, both the original
biologicmedicine and its biosimilar version(s) are included in
the formulary—physicians can choose which biologic should
be prescribed for a patient: this represents a more passive
biosimilar policy and potentially slower uptake of biosimilars
[8]. Introduction of prescription quotasmay also facilitate the
uptake of biosimilars. In Hungary, for example, physicians
are incentivized to prescribe the preferred biologics in a
minimum 40% of their current patients [33]. A similar, but
less ambitious, approach was reported from Belgium: as a
consequence of a multistakeholder agreement, biosimilars
should be used in at least 20% of new patients [44].
Uncertainty related to switching may be handled by
risk-management strategies [9]. Ex post risk-management
strategy mandates postmarketing data collection and a
risk-management plan for manufacturers of biosimilar
products and/or health care institutions. Our results indicate
that a conceptual framework for a strengthened pharma-
covigilance system for biosimilars based on additional real-
world data collection exists in all countries. France is a good
example for the significance of such data collection: based
on real-world evidence, the French drug agency changed its
initially negative attitude towards switching and stated that
switching patients to biosimilars under medical supervision
should not be discouraged [45]. According to a recent survey
conducted in New Zealand, most physicians indicated that
they would prescribe biosimilars for clinical conditions in
which biosimilars are cost-effective alternatives to original
biologicmedicines. However, they also highlighted the neces-
sity of communication guidance for clinicians on how to
explain biosimilars effectively to patients in order to reduce
potential objections [46].
A recent paper summarizes potential government inter-
ventions to facilitate the utilisation of biosimilars in lower
income countries (see Table 3) [9].
Generalizability of our findings is limited, as our policy
research engaged only two experts (representing both public
and private sectors) in each participant country. Although
survey respondents had the opportunity to consult with
additional local experts, their opinion may not be fully
representative for the entire country. However, as our find-
ings are in line with conclusions of other publications, the
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trends presented in this study may provide relevant input
to reconsideration of current biosimilar policies in CEE/CIS
countries.
5. Conclusion
Our survey indicated a significant unmet need for more
affordable biologic therapies in the CEE/CIS countries. The
key concerns about the increased utilisation of biosimi-
lars were limited evidence on therapeutic equivalence and
expected adverse immunologic reactions. Nevertheless, the
role of biosimilars in increasing patient access to reimbursed
biologics was acknowledged by almost all experts. Policy-
makers have to take a strategic approach to increase soci-
etal benefit from biosimilar medicines. Relying on free-
market incentives may not be strong enough; hence, active
government interventions instead of “passive disinvestment”
policies are needed to correct for current access limitations.
Disclosure
The content of this paper, as well as the views and opinions
expressed therein, are those of the authors and not the
organizations that employ them.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Acknowledgments
Syreon Research Institute received research grant for devel-
oping and evaluating the research survey.
References
[1] World Health Organisation, “Life expectancy, 2015,” http://apps
.who.int/gho/data/view.main.SDG2016LEXv?lang=en.
[2] Z. Kalo´, L. Annemans, and L. P. Garrison, “Differential pricing
of new pharmaceuticals in lower income European countries,”
Expert Review of Pharmacoeconomics&Outcomes Research, vol.
13, no. 6, pp. 735–741, 2013.
[3] P. G. Kanavos and S. Vandoros, “Determinants of branded
prescription medicine prices in OECD countries,” Health Eco-
nomics, Policy and Law, vol. 6, no. 3, pp. 337–367, 2011.
[4] P. Elek, E. Taka´cs, G. Mere´sz, and Z. Kalo´, “Implication of
external price referencing and parallel trade on pharmaceutical
expenditure: indirect evidence from lower-income European
countries,” Health Policy and Planning, vol. 32, no. 3, pp. 349–
358, 2017.
[5] A. Inotai, G. Petrova, D. Vitezic, and Z. Kalo´, “Benefits of invest-
ment into modern medicines in Central-Eastern European
countries,” Expert Review of Pharmacoeconomics & Outcomes
Research, vol. 14, no. 1, pp. 71–79, 2014.
[6] Z. Kalo´, K. Landa, T. Dolezˇal, and Z. Voko´, “Transferabil-
ity of National Institute for Health and Clinical Excellence
recommendations for pharmaceutical therapies in oncology
to Central-Eastern European countries,” European Journal of
Cancer Care, vol. 21, no. 4, pp. 442–449, 2012.
[7] E. Moorkens, C. Jonker-Exler, I. Huys, P. Declerck, S. Simoens,
and A. G. Vulto, “Overcoming barriers to the market access
of biosimilars in the European union: The case of biosimilar
monoclonal antibodies,” Frontiers in Pharmacology, vol. 7,
article no. 193, 2016.
[8] C. Re´muzat, A. Kapus´niak, A. Caban et al., “Supply-side
and demand-side policies for biosimilars: an overview in 10
European member states,” Journal of Market Access & Health
Policy, vol. 5, no. 1, p. 1307315, 2017.
[9] A. Inotai, M. Csana´di, D. Vitezic, and et al., “Policy Practices to
Maximise Social Benefit from Biosimilars,” Journal of Bioequiv-
alence & Bioavailability, vol. 9, no. 4, pp. 467–472, 2017.
[10] Z. Kalo´, Z. Voko´, A. O¨sto¨r et al., “Patient access to reimbursed
biological disease-modifying antirheumatic drugs in the Euro-
pean region,” Journal of Market Access & Health Policy, vol. 5,
no. 1, article no. 1345580, 2017.
[11] L. P. Garrison, “Pharmacoeconomics and Drug Pricing,” in
Biotechnology and Biopharmaceuticals: Transforming Proteins
and Genes into Drugs, R. J. Y. Ho and M. Gibaldi, Eds., John
Wiley and Sons, 2nd edition, 2013.
[12] E. Choy and I. A. Jacobs, “Biosimilar safety considerations in
clinical practice,” Seminars in Oncology, vol. 41, no. 1, pp. S3–
S14, 2014.
[13] B. Calo-Ferna´ndez and J. L. Mart´ınez-Hurtado, “Biosimilars:
Company strategies to capture value from the biologicsmarket,”
Pharmaceuticals, vol. 5, no. 12, pp. 1393–1408, 2012.
[14] C. E. Emmanouilides, M. I. Karampola, and M. Beredima,
“Biosimilars: Hope and concern,” Journal of Oncology Pharmacy
Practice, vol. 22, no. 4, pp. 618–624, 2016.
[15] R. Mu¨ller, C. Renner, C. Gabay, G. Cassata, A. Lohri, and P.
Hasler, “The advent of biosimilars: Challenges and risks,” Swiss
Medical Weekly, vol. 144, Article ID w13980, 2014.
[16] J. Braun and A. Kudrin, “Switching to biosimilar infliximab
(CT-P13): Evidence of clinical safety, effectiveness and impact
on public health,” Biologicals, vol. 44, no. 4, pp. 257–266, 2016.
[17] H. Schellekens, “Biosimilar therapeutics—what do we need to
consider?” NDT Plus, vol. 2, supplement 1, pp. i27–i36, 2009.
[18] A. Kudrin, I. Knezevic, J. Joung, and H. N. Kang, “Case studies
on clinical evaluation of biosimilar monoclonal antibody: Sci-
entific considerations for regulatory approval,” Biologicals, vol.
43, no. 1, pp. 1–10, 2015.
[19] R. Markus, J. Liu, M. Ramchandani, D. Landa, T. Born, and
P. Kaur, “Developing the Totality of Evidence for Biosimilars:
Regulatory Considerations and Building Confidence for the
Healthcare Community,” BioDrugs, vol. 31, no. 3, pp. 175–187,
2017.
[20] V. Strand, A. Balsa, J. Al-Saleh et al., “Immunogenicity of
Biologics in Chronic Inflammatory Diseases: A Systematic
Review,” BioDrugs, vol. 31, no. 4, pp. 299–316, 2017.
[21] S. R. Feldman, “Inflammatory diseases: Integrating biosimilars
into clinical practice,” Seminars in Arthritis and Rheumatism,
vol. 44, no. 6, pp. S16–S21, 2015.
[22] W. Jeske, J. M. Walenga, D. Hoppensteadt, and J. Fareed,
“Update on the safety and bioequivalence of biosimilars - Focus
on enoxaparin,” Journal of Drug, Healthcare and Patient Safety,
vol. 5, no. 1, pp. 133–141, 2013.
[23] P. Kurki, L. van Aerts, E. Wolff-Holz, T. Giezen, V. Skibeli,
and M. Weise, “Interchangeability of Biosimilars: A European
Perspective,” BioDrugs, vol. 31, no. 2, pp. 83–91, 2017.
[24] A. Inotai, C. P. Prins, M. Csana´di, D. Vitezic, C. Codreanu,
and Z. Kalo´, “Is there a reason for concern or is it just hype?
BioMed Research International 9
– A systematic literature review of the clinical consequences
of switching from originator biologics to biosimilars,” Expert
Opinion on Biological Therapy, vol. 17, no. 8, pp. 915–926, 2017.
[25] V. Annese, M. Vecchi, F. Bossa et al., “Use of biosimilars in
inflammatory bowel disease: Statements of the ItalianGroup for
Inflammatory Bowel Disease,” Digestive and Liver Disease, vol.
46, no. 11, pp. 963–968, 2014.
[26] F. Atzeni, M. Sebastiani, and C. Ricci, “Position paper of Italian
rheumatologists on the use of biosimilar drugs,” Clinical and
Experimental Rheumatology, vol. 33, no. 1, pp. 1–4, 2014.
[27] G. Barosi, A. Bosi, M. P. Abbracchio et al., “Key concepts and
critical issues on epoetin and filgrastim biosimilars: a position
paper from the Italian Society of Hematology, Italian Society of
Experimental Hematology, and Italian Group for BoneMarrow
Transplantation,” Haematologica, vol. 96, no. 7, pp. 937–942,
2011.
[28] F. Gomollo´n, “Biosimilars: Are they bioequivalent?” Digestive
Diseases, vol. 32, pp. 82–87, 2014.
[29] L. Gula´csi, V. Brodszky, P. Baji, F. Rencz, and M. Pe´ntek, “The
Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A
Budget Impact Analysis in 28 EuropeanCountries,”Advances in
Therapy, vol. 34, no. 5, pp. 1128–1144, 2017.
[30] C. Re´muzat, J. Dorey, O. Cristeau, D. Ionescu, G. Radie`re, and
M. Toumi, “Key drivers for market penetration of biosimilars in
Europe,” Journal of Market Access & Health Policy, vol. 5, no. 1,
p. 1272308, 2017.
[31] N. Swartenbroekx, Farfan-Portet, J. Espı´n, and S. Gerkens,
“Incentives for market penetration of biosimilars in Belgium
and in five European countries,” Journal de Pharmacie de
Belgique, no. 4, pp. 36–46, 2014.
[32] P. Dylst, A. Vulto, and S. Simoens, “Barriers to the uptake
of biosimilars and possible solutions: A Belgian case study,”
PharmacoEconomics, vol. 32, no. 7, pp. 681–691, 2014.
[33] P. Kawalec, E. Stawowczyk, T. Tesar et al., “Pricing and Reim-
bursement of Biosimilars in Central and Eastern European
Countries,” Frontiers in Pharmacology, vol. 8, 2017.
[34] Z. Kalo´, A.-P. Holtorf, R. Alfonso-Cristancho et al., “Need
for multicriteria evaluation of generic drug policies,” Value in
Health, vol. 18, no. 2, pp. 346–351, 2015.
[35] B. Parkinson, C. Sermet, F. Clement, and et al., “Disinvestment
andValue-Based Purchasing Strategies for Pharmaceuticals: An
International Review,” Pharmacoeconomics, vol. 33, no. 9, pp.
905–924, 2015.
[36] F. Rencz, M. Pentek, M. Bortlik et al., “Biological therapy in
inflammatory bowel diseases: Access in Central and Eastern
Europe,”World Journal of Gastroenterology, vol. 21, no. 6, p. 1728,
2015.
[37] “Celltrion Remicade biosimilar gathers momentum in EU,
2015,” http://www.pharmatimes.com/news/celltrion remicade
biosimilar gathers momentum in eu 971086.
[38] B. Lunddahl, “Pharmacovigilance on biologicals and biosimi-
lars: A Danish perspective,” GaBI Journal, vol. 5, no. 3, pp. 123-
124, 2016.
[39] K. Papamichael, T. Van Stappen, V. Jairath et al., “Review
article: Pharmacological aspects of anti-TNF biosimilars in
inflammatory bowel diseases,” Alimentary Pharmacology &
Therapeutics, vol. 42, no. 10, pp. 1158–1169, 2015.
[40] K. McKeage, “A Review of CT-P13: an Infliximab Biosimilar,”
BioDrugs, vol. 28, no. 3, pp. 313–321, 2014.
[41] H. C. Ebbers, M. Muenzberg, and H. Schellekens, “The safety
of switching between therapeutic proteins,” Expert Opinion on
Biological Therapy, vol. 12, no. 11, pp. 1473–1485, 2012.
[42] “Biologics in the Polish health system, 2015,” http://www
.infarma.pl/assets/files/innowacje/Biologics in the Polish
health system.pdf.
[43] A. V. Pinheiro, M. Vithlani, K. Sarnataro, and et al., “Impact of
market access factors in the adoption of biosimilar anti-TNFs
across Europe. Precision for Value report, 2016,” http://www
.precisionforvalue.com/wp-content/uploads/2016/05/Impact-
of-Market-Access-Factors-Across-Europe.pdf.
[44] “Pacte d’avenir pour le patient avec l’industrie pharmaceutique,
2015,” http://www.deblock.belgium.be/sites/default/files/arti-
cles/20150727%20Pacte%20d’avenir.pdf.
[45] “ANSM report, E´tat des lieux sur lesme´dicaments biosimilaires,
2016,” http://ansm.sante.fr/var/ansm site/storage/original/ap-
plication/c35f47c89146b71421a275be7911a250.pdf.
[46] A. Hemmington, N. Dalbeth, P. Jarrett et al., “Medical special-
ists’ attitudes to prescribing biosimilars,” Pharmacoepidemiol-
ogy and Drug Safety, vol. 26, no. 5, pp. 570–577, 2017.
